TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
Johnson & Johnson JNJ suffered a setback when the FDA issued a complete response letter (CRL) in response to the company’s supplemental new drug application (sNDA) for the once-monthly long-acting ...
A Drug's Impact on Global Symptoms and Its Effect on Positive Symptoms Are the Attributes that Most Influence Surveyed Psychiatrists' Prescribing Decisions in Schizophrenia, According to a New Report ...
The FINANCIAL — A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA (paliperidone palmitate) was effective six months longer than commonly prescribed oral ...
Johnson & Johnson wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy ...
Janssen announced submission of a supplemental New Drug Application (sNDA) to the FDA for a label change to include new data demonstrating significantly delayed time to relapse in patients taking ...
August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results